Vaccine News and Research

Latest Vaccine News and Research

GSK will ensure experimental malaria vaccine is affordable, CEO says

GlaxoSmithKline CEO Andrew Witty said Wednesday the company would ensure that if an experimental malaria vaccine works, it would be priced reasonably, Reuters reports. "The vaccine, called Mosquirix [or RTS,S] and the first malaria shot to make it to final-stage trials, is creating a buzz ahead of a conference of 1,500 malaria experts in Nairobi next week," writes Reuters.

29 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

AstraZeneca, Third quarter revenue increased by 10 percent at constant exchange rates (CER) to $8,200 million.

29 Oct 2009

Today's opinions and editorials

The federal government could treat Indian Country, at least for health programs, as the 51st state. This seems to me a practical application of the nation-to-nation relationship (Mark Trahant, 10/29).

29 Oct 2009

Third-quarter 2009 financial results of Antigenics announced

Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted.

29 Oct 2009

First Edition: October 29, 2009

Today's headlines are all about the unveiling of the House health bill -- expected later this morning.

29 Oct 2009

Centene takes proactive approach to prevent influenza virus through its Fluvention program

Centene Corporation takes a proactive approach with education around how to prevent the influenza virus each year through its FluventionTM program.

29 Oct 2009

Bio-Pharmaceutical Summit 2009 to be held in China

Biotechnology is an emerging industry to which many countries are attaching great importance. China is determined to grasp the great opportunities brought by the biotechnology revolution. Biotech industry will become a pillar of China’s hi-tech sector, in which bio-pharmaceutical is playing a leading role.

29 Oct 2009

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

President Barack Obama declared H1N1 a national emergency this weekend, a status that will give the federal government greater flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether through natural disease transmission or manmade bioterrorist attacks, according to a new video from the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

29 Oct 2009

Poison control centers to take calls for H1N1

The same reassuring voice on the telephone line when you fear you've had a poison emergency may be the same person answering your questions about the H1N1 flu pandemic.

29 Oct 2009

Comprehensive H1N1 influenza health information centre launched in Canada

Canadians are seeking credible information concerning the H1N1 (human swine flu) virus. As a leading Canadian source of ealth information, www.medbroadcast.com has launched a one-stop comprehensive national H1N1 (human swine flu) Influenza Health information centre (www.medbroadcast.com/H1N1). This information centre will help meet the needs of Canadians in search of useful, credible, and accurate H1N1 information.

29 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

Gates Foundation praises U.S. global health investments, calls for 15-year goal of cutting child deaths worldwide by nearly half

As part of a "major push to convince the United States to maintain government spending on worldwide health initiatives, despite the financial crisis and a soaring U.S. budget deficit," the Bill & Melinda Gates Foundation is urging U.S. policymakers to commit to cutting "the number of child deaths each year, from 9 million to 5 million" by 2025, CNN reports (Evans, 10/28).

28 Oct 2009

CDC says U.S. H1N1 vaccine supplies on the rise; Senators question government's handling of H1N1 vaccination program

Supplies of the H1N1 (swine flu) vaccine are steadily increasing in the U.S. and should soon be more widely accessible in the next two weeks, the CDC said on Tuesday, CQ HealthBeat reports. During a press briefing, CDC Director Thomas Frieden said that 22.4 million vaccine doses are now available for states to order (Norman, 10/27). "We're beginning to get to significant increases in the availability," Frieden said.

28 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

GSK will ensure experimental malaria vaccine is affordable, CEO says

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

AstraZeneca bolsters revenue with Toprol-XL and H1N1 vaccine sales

Today's opinions and editorials

Third-quarter 2009 financial results of Antigenics announced

First Edition: October 29, 2009

Centene takes proactive approach to prevent influenza virus through its Fluvention program

Bio-Pharmaceutical Summit 2009 to be held in China

Simcere Pharmaceutical Group to control a 50.77% stake in Jiangsu Yanshen

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

Modern techniques can reduce current shortage of H1N1 vaccine in the U.S.

Poison control centers to take calls for H1N1

Comprehensive H1N1 influenza health information centre launched in Canada

Impact of wellness programs on pharmaceutical, diagnostic and device markets

NIH awards contract to LRRI for anthrax research

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Gates Foundation praises U.S. global health investments, calls for 15-year goal of cutting child deaths worldwide by nearly half

CDC says U.S. H1N1 vaccine supplies on the rise; Senators question government's handling of H1N1 vaccination program

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in